admin

Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, randomised, controlled trial. The Lancet, 2021. Stéphane Gaudry, David Hajage, Laurent Martin-Lefevre, Saïd Lebbah, Guillaume Louis, Sébastien Moschietto, Dimitri Titeca-Beauport, Béatrice La Combe, Bertrand Pons, Nicolas de Prost, Sébastien Besset, Alain Combes, Adrien Robine, Marion Beuzelin, Julio Badie, Guillaume Chevrel, Julien Bohé, Elisabeth Coupez, Nicolas Chudeau, Saber Barbar, Christophe Vinsonneau, Jean-Marie Forel, Didier Thevenin, Eric Boulet, Karim Lakhal, Nadia Aissaoui, Steven […]

Endothelial-Specific Deletion of CD146 Protects Against Experimental Glomerulonephritis in Mice Hypertension, 2021. Ahmed Abed, Aurélie S. Leroyer, Panagiotis Kavvadas, Florence Authier, Richard Bachelier, Alexandrine Foucault-Bertaud, Nathalie Bardin, Clemens D. Cohen, Maja T. Lindenmeyer, Magali Genest, Ahmad Joshkon, Noémie Jourde-Chiche, Stéphane Burtey, Marcel Blot-Chabaud, Françoise Dignat-George, Christos E. Chadjichristos.

This study recently published in the Lancet is an individual patient data meta-analysis (IPDMA) of randomised clinical trials evaluating initiation strategies for renal replacement therapy (RRT) in the context of severe acute kidney injury.